PD-1 of Sigmodon hispidus: Gene identification, characterization and preliminary evaluation of expression in inactivated RSV vaccine-induced enhanced respiratory disease.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 08 2019
Historique:
received: 18 10 2018
accepted: 29 07 2019
entrez: 14 8 2019
pubmed: 14 8 2019
medline: 28 10 2020
Statut: epublish

Résumé

Sigmodon hispidus or cotton rat is an excellent animal model for studying human infections of respiratory viruses including respiratory syncytial virus (RSV), which is the leading cause of hospitalization in infants and causes high rates of infection in the elderly and immunocompromised patient populations. Despite several decades of research, no vaccine has been licensed whereas inactivated vaccines have been shown to induce severe adverse reaction in a clinical trial, with other forms of RSV vaccine also found to induce enhanced disease in preclinical animal studies. While arguably the cotton rat is the best small animal model for evaluation of RSV vaccines and antivirals, many important genes of the immune system remain to be isolated. Programmed cell death-1 (PD-1) plays an integral role in regulating many aspects of immunity by inducing suppressive signals. In this study, we report the isolation of mRNA encoding the cotton rat PD-1 (crPD-1) and characterization of the PD-1 protein. crPD-1 bound to its cognate ligand on dendritic cells and effectively suppressed cytokine secretion. Moreover, using the newly acquired gene sequence, we observed a decreased level of crPD-1 levels in cotton rats with enhanced respiratory disease induced by inactivated RSV vaccine, unraveling a new facet of vaccine-induced disease.

Identifiants

pubmed: 31406266
doi: 10.1038/s41598-019-48225-x
pii: 10.1038/s41598-019-48225-x
pmc: PMC6690999
doi:

Substances chimiques

Cytokines 0
Programmed Cell Death 1 Receptor 0
RNA, Messenger 0
RNA, Viral 0
Respiratory Syncytial Virus Vaccines 0
Vaccines, Inactivated 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11638

Références

J Infect Dis. 2015 Dec 15;212(12):1999-2010
pubmed: 26019284
Immunity. 2004 Mar;20(3):337-47
pubmed: 15030777
Am J Dis Child. 1986 Jun;140(6):543-6
pubmed: 3706232
Am J Epidemiol. 1969 Apr;89(4):422-34
pubmed: 4305198
Biologicals. 2009 Jun;37(3):152-9
pubmed: 19394861
Expert Rev Vaccines. 2017 Apr;16(4):351-360
pubmed: 27841687
Am J Epidemiol. 1969 Apr;89(4):435-48
pubmed: 4305199
Nature. 2006 Feb 9;439(7077):682-7
pubmed: 16382236
Annu Rev Med. 2018 Jan 29;69:301-318
pubmed: 29414259
Pediatrics. 2013 Aug;132(2):e341-8
pubmed: 23878043
J Immunol. 2011 Mar 1;186(5):3093-103
pubmed: 21263070
Lab Anim. 2002 Oct;36(4):357-72
pubmed: 12396279
Infect Immun. 1983 Oct;42(1):81-7
pubmed: 6352505
J Immunol. 2007 Oct 15;179(8):5099-108
pubmed: 17911595
J Immunol. 2016 Mar 15;196(6):2431-7
pubmed: 26945088
Exp Biol Med (Maywood). 2002 Oct;227(9):799-802
pubmed: 12324660
J Exp Med. 2002 Sep 16;196(6):859-65
pubmed: 12235218
Int Immunol. 1996 May;8(5):765-72
pubmed: 8671665
Exp Lung Res. 2005 Sep;31 Suppl 1:77
pubmed: 16395866
J Exp Med. 2000 Mar 6;191(5):891-8
pubmed: 10704469
J Infect Dis. 2011 Jan 1;203(1):85-94
pubmed: 21148500
J Infect Dis. 2002 Jun 15;185(12):1780-5
pubmed: 12085325
Sci Rep. 2018 Apr 30;8(1):6777
pubmed: 29712964
J Gen Virol. 2001 Dec;82(Pt 12):2881-2888
pubmed: 11714962
Microbiol Immunol. 2016 Apr;60(4):234-42
pubmed: 26865035
Annu Rev Immunol. 2011;29:621-63
pubmed: 21314428
Curr Top Microbiol Immunol. 2011;350:17-37
pubmed: 21061197
Int Immunol. 1996 May;8(5):773-80
pubmed: 8671666
Curr Top Microbiol Immunol. 2009;330:89-110
pubmed: 19203106
J Virol. 1999 Oct;73(10):8485-95
pubmed: 10482601
J Mol Biol. 2018 Jul 20;430(15):2244-2248
pubmed: 29391170
Cancer J. 2014 Jul-Aug;20(4):265-71
pubmed: 25098287
Front Immunol. 2019 Mar 29;10:597
pubmed: 30984178
Science. 2009 Aug 21;325(5943):1006-10
pubmed: 19608860
J Mol Biol. 2007 May 4;368(3):652-65
pubmed: 17362988
Methods Mol Biol. 2014;1172:257-62
pubmed: 24908312
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13866-71
pubmed: 11698646
Immunity. 2007 Oct;27(4):670-84
pubmed: 17950003
Blood. 2009 Jun 4;113(23):5811-8
pubmed: 19339692
Nature. 2009 Mar 12;458(7235):206-10
pubmed: 19078956
Lab Invest. 1999 Nov;79(11):1385-92
pubmed: 10576209
Vaccine. 2006 Jun 5;24(23):5027-35
pubmed: 16675071
Mucosal Immunol. 2015 Jul;8(4):746-59
pubmed: 25465101
Gene Ther. 2004 Jun;11(11):924-32
pubmed: 15085173
Eur J Pediatr. 2005 Oct;164(10):607-15
pubmed: 15965766
J Infect Dis. 2007 Feb 15;195(4):511-8
pubmed: 17230410
Proc Am Thorac Soc. 2005;2(2):110-5
pubmed: 16113477
J Virol. 1986 Mar;57(3):721-8
pubmed: 2419587
Pediatr Infect Dis J. 2007 Oct;26(10):904-8
pubmed: 17901795
Lancet. 2010 May 1;375(9725):1545-55
pubmed: 20399493
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
Immunity. 2014 Feb 20;40(2):235-247
pubmed: 24440150
J Clin Invest. 2012 Aug;122(8):2967-82
pubmed: 22797302
Lab Anim (NY). 2013 May;42(5):170-6
pubmed: 23604159
PLoS One. 2018 Jul 27;13(7):e0199067
pubmed: 30052641
Arch Pediatr Adolesc Med. 2001 Jan;155(1):95-6
pubmed: 11177073
Am J Epidemiol. 1969 Apr;89(4):449-63
pubmed: 4305200
J Virol. 2008 Mar;82(5):2040-55
pubmed: 17928346
Future Virol. 2011 Aug;6(8):963-973
pubmed: 21887154
Future Microbiol. 2009 Apr;4(3):279-97
pubmed: 19327115
Am J Epidemiol. 1969 Apr;89(4):405-21
pubmed: 4305197
J Immunol. 2015 May 1;194(9):4545-54
pubmed: 25810391

Auteurs

Abenaya Muralidharan (A)

Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON, Canada.
Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Louise Larocque (L)

Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON, Canada.

Marsha Russell (M)

Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON, Canada.

Marybeth Creskey (M)

Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON, Canada.

Changgui Li (C)

National Institute for Food and Drug Control and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.

Wangxue Chen (W)

Human Therapeutics Portfolio, National Research Council of Canada, Ottawa, ON, Canada.

Gary Van Domselaar (G)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.

Jingxin Cao (J)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.

Terry Cyr (T)

Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON, Canada.

Michael Rosu-Myles (M)

Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON, Canada.
Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Lisheng Wang (L)

Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Xuguang Li (X)

Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, ON, Canada. Sean.Li@canada.ca.
Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. Sean.Li@canada.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH